EP1109575A2 - Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1 - Google Patents

Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1

Info

Publication number
EP1109575A2
EP1109575A2 EP99949907A EP99949907A EP1109575A2 EP 1109575 A2 EP1109575 A2 EP 1109575A2 EP 99949907 A EP99949907 A EP 99949907A EP 99949907 A EP99949907 A EP 99949907A EP 1109575 A2 EP1109575 A2 EP 1109575A2
Authority
EP
European Patent Office
Prior art keywords
virus
hiv
shiv
infection
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99949907A
Other languages
German (de)
English (en)
Inventor
Opendra Narayan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Kansas Medical Center
Original Assignee
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Kansas Medical Center filed Critical University of Kansas Medical Center
Publication of EP1109575A2 publication Critical patent/EP1109575A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention teaches an avirulent HIV-1 virus, wherein the vpu gene of the HIV-1 virus has been rendered non-functional or deleted.
  • the HIV-1 virus may have a non-functional or deleted nef gene.
  • the instant invention also encompasses a HIV-1 /HIV-2 chimeric virus wherein the chimeric DNA comprises HIV-2 LTR, gag, pol, and nef ' genes and HIV-1 env, tat, rev, vpu genes, where said vpu gene is rendered non-functional or is deleted.
  • the nef gene is optionally rendered non-functional or deleted.
  • SIV mac which is closely related to HIV-2 and SIVsm, causes AIDS in macaques and has been extensively used in vaccine studies. Macaques vaccinated with attenuated strains of SIV mac , produced by deleting auxiliary genes, particularly nef, resisted infection after challenge with virulent strains of SIVmac (Daniel, M. D., Kirchhoff, F., Czajak, S. C, Sehgal, P. K. & Desrosiers, R. C. Science 258, 1938-1941 (1992); Almond, N., Kent, K., Cranage, M., Rud, E., Clarke, B. & Stott, E. J.
  • SHIV-4 Construction of Avpu nef SHIV-4 .
  • the original SHIV-4 DNA consisted of 2 plasmids with the 5 ' and 3 ' regions, respectively. All manipulations were performed with the p3 ' SHIV-4.
  • plasmid pUC19 was digested with Sspl, blunt-ended by Klenow fragment of DNA polymerase and ligated to generate pDS.
  • the Sphl-Kpnl fragment (nt 6450 to 6985) of p3 ' SHIV-4 was subcloned into pDS to generate pDSvpu.
  • Plasma obtained from the femoral vein was centrifuged to separate plasma and buffy coats. Plasma was assayed for p27 using a capture ELISA kit (Coulter Laboratories, Hialeah, FL), and for infectivity in C8166 cells. Peripheral blood mononuclear cells (PBMC) were separated from buffy coats by centrifugation through a Ficoll-Paque (Pharmacia) density gradient.
  • PBMC Peripheral blood mononuclear cells
  • Week -7 to -1 were after Cornea inoculation; Week 1 to 4 after Intra-dermal inoculation.
  • SIVpolC (5'ACCAATCCATACAACACC3') (SEQ ID NO:7) and SIVpolD (5'CTGCCCAATTTAATACTCC3') (SEQ ID NO:8) 3 mM MgCl 2 and 1.25 U of Taq enzyme (Sigma, St. Louis, MO.), and a further 35 cycles were performed with the following thermal profile: 97°C for 1 minute, 55°C for 2 minutes and 72°C for 5 minutes, 1 cycle 94°C for 30 seconds, 55°C for 30 seconds, 72°C for 45 seconds, with an additional extension/cycle, 33 cycles: 94°C for 30 seconds, 55°C for 30 seconds, and 72°C for 6 minutes.
  • the vpu that was amplified is indicated as C (challenge vims [SH1V KLM ] or V (vaccine vims). Both challenge and vaccine vims sequences were amplified from Pna
  • Four of these six vaccinated macaques resisted productive infection and disease following intravaginal challenge with SHIV KLM ( ⁇ 2 test, P 0.102).
  • V-II virus DNA and C-virus DNA Comparison of these sequences with those of V-II virus DNA and C-virus DNA showed that the newly isolated viruses have scattered mutations in gp ⁇ 2Q and nef.
  • the viruses isolated from PEy and PW1 in the V-II group are variants of V-II virus, and the agent isolated from 8124 is a variant of C-virus (data not shown). There was no evidence of recombination between V- and C-virus DNAs in any of the three newly derived agents.
  • CD4 + T cells were equally responsive to viral antigens and CTLs recognized epitopes in all three of the structural proteins of the virus and in autologous CD4 + T cells infected with C-virus (Table 18). Although the study on CMI responses was not initiated until approximately 40 weeks post-challenge, this immune response was already in place in animals in both groups when, in the V-II group, not only had infectious virus been eliminated, but viral DNA was in the process of being eliminated in most of the animals. This contrasted with the V-I group in which infectious C-virus persisted.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne le SHIV pathogène à l'origine du SIDA chez les singes, l'élaboration d'un virus destiné à s'utiliser dans des vaccins contre le SHIV pathogène et le VIH-1, ainsi que des méthodes de vaccination thérapeutique et prophylactique de prévention ou d'inhibition d'infections et/ou de maladies dues au VIH-1. La présente invention concerne également l'élaboration d'un virus actif modifié destiné à s'utiliser dans des vaccins contre VIH-1, ainsi que des méthodes de vaccination prophylactique et thérapeutique de prévention ou d'inhibition d'infections et/ou de maladies dues au VIH-1. La présente invention concerne enfin l'utilisation de vaccins génétiques viraux destinés au traitement et à la prévention d'infections et/ou de maladies dues au VIH.
EP99949907A 1998-09-29 1999-09-28 Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1 Withdrawn EP1109575A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10214398P 1998-09-29 1998-09-29
US102143P 1998-09-29
PCT/US1999/022349 WO2000018430A2 (fr) 1998-09-29 1999-09-28 Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1

Publications (1)

Publication Number Publication Date
EP1109575A2 true EP1109575A2 (fr) 2001-06-27

Family

ID=22288338

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99949907A Withdrawn EP1109575A2 (fr) 1998-09-29 1999-09-28 Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1

Country Status (4)

Country Link
EP (1) EP1109575A2 (fr)
AU (1) AU6268199A (fr)
CA (1) CA2345959A1 (fr)
WO (1) WO2000018430A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013315631B2 (en) * 2012-09-11 2018-04-19 The Regents Of The University Of California HIV-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7276198A (en) * 1997-05-02 1998-11-27 University Of Kansas Medical Center Live virus vaccines to protect primates from hiv-1 infection and disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0018430A2 *

Also Published As

Publication number Publication date
WO2000018430A3 (fr) 2000-07-06
WO2000018430A2 (fr) 2000-04-06
CA2345959A1 (fr) 2000-04-06
AU6268199A (en) 2000-04-17

Similar Documents

Publication Publication Date Title
Shibata et al. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus
Lu et al. Simian immunodeficiency virus DNA vaccine trial in macaques
Joag et al. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
NORLEY et al. Protection from pathogenic SIVmac challenge following short-term infection with a nef-deficient attenuated virus
Martinez et al. Contrasting adult and infant immune responses to HIV infection and vaccination
Enose et al. Protection by intranasal immunization of a nef-deleted, nonpathogenic SHIV against intravaginal challenge with a heterologous pathogenic SHIV
Miyake et al. Induction of HIV‐specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV‐capturing nanospheres in macaques
Bailey An assessment of the role of chimpanzees in AIDS vaccine research
Putkonen et al. Long–term protection against SIV–induced disease in macaques vaccinated with a live attenuated HIV–2 vaccine
Foresman et al. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques
Picker et al. The CD4+ T cell response to HIV-1
Shibata et al. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1
Geretti Simian immunodeficiency virus as a model of human HIV disease
Quinnan Jr et al. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells
McKee et al. Immune responses against SIV envelope glycoprotein, using recombinant SV40 as a vaccine delivery vector
Kumar et al. Sequential immunization of macaques with two differentially attenuated vaccines induced long-term virus-specific immune responses and conferred protection against AIDS caused by heterologous simian human immunodeficiency virus (SHIV89. 6P)
Mackay et al. Presence of intact vpu and nef genes in nonpathogenic SHIV is essential for acquisition of pathogenicity of this virus by serial passage in macaques
EP1073461B1 (fr) Chimeres virales comprenant des elements genetiques de caev et de vih-1
Liu et al. Immunoprophylaxis against AIDS in macaques with a lentiviral DNA vaccine
EP1109575A2 (fr) Vaccins a virus actif destines a la protection de primates contre des infections et maladies dues au vih-1
WAKRIM et al. Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251
Ui et al. Protective immunity of gene‐deleted SHIVs having an HIV‐1 Env against challenge infection with a gene‐intact SHIV
Kumar et al. Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration
WO1998050070A1 (fr) Vaccins a base de virus vivants visant a proteger des primates contre l'infection et la maladie dues au vih-1
Sealy et al. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010329

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20010710

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030611